U.S. Commercialization Insights
Written for global manufacturers entering the United States and emerging U.S. biopharma teams building commercial infrastructure for the first time. Research is cited, limits are stated, and the human consequences stay visible.
Research · Evidence · Limits · Decisions
What first-time U.S. launchers often discover too late—and the decisions that should be made before one approval date becomes the only date anyone can see.
By Sharon O’Dell
Founder · Upper Echelon Management
A practical way to decide what to build, what to buy, what to rent, and what not to fund yet.
By Sharon O’Dell
Founder · Upper Echelon Management
What the distance between FDA approval and patient access teaches first-time U.S. launchers.
By Sharon O’Dell
Founder · Upper Echelon Management
Why we publish
UEM publishes to help commercial leaders see decisions, dependencies, and evidence gaps earlier. Each article connects practical launch questions with the operating principles behind UEM and RxLaunchOS.
“The most useful answer is sometimes a clearer question, a visible assumption, or an honest statement that the evidence is not ready.”
Sharon O’Dell · Founder
Rexa is Upper Echelon Management's public AI concierge. Do not share patient information, passwords, trade secrets, or confidential company information.